Assessment of Safety, Immunogenicity and Efficacy of R21/Matrix-M1 Malaria Vaccine in Healthy WOCBP in Mali

NCT06080243 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

330

Enrollment

OTHER

Sponsor class

Conditions

Healthy Women of Child Bearing Potential

Interventions

BIOLOGICAL: R21/Matrix-M1
BIOLOGICAL: Saline and R21/Matrix-M1
OTHER: Sterile isotonic (0.9%) normal saline

Sponsor

University of Oxford

Collaborators

Malaria Research and Training Center, Bamako, Mali
European Vaccine Initiative